Pabst, Kim M. http://orcid.org/0000-0002-9234-0795
Kessler, Lukas
Ferdinandus, Justin
Hamacher, Rainer
Bartel, Timo
Siveke, Jens T.
Nader, Michael
Brandenburg, Tim
Desaulniers, Mélanie
Herrmann, Ken
Fendler, Wolfgang P.
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 1 May 2024
Accepted: 6 July 2024
First Online: 18 July 2024
Declarations
:
: The retrospective analysis was approved by the Ethics Committee of the Medical Faculty of the University Hospital Essen (permits no. 20-9485-BO/20-9777-BO/19-8991-BO). The study adhered to the ethical standards of the 1964 Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from all individual participants included in the study.
: Written informed consent was obtained from the patient for publication of this study and accompanying images.
: KMP: has received a Clinician Scientist Stipend of the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by the faculty of medicine and Deutsche Forschungsgemeinschaft (DFG); travel fees: IPSEN; research funding: Bayer; consultant: Novartis. LK: consultant: AAA, BTG; fees: Sanofi. RH: has received a Clinician Scientist Stipend of the UMEA sponsored by the faculty of medicine and DFG; travel grants: Lilly, Novartis, PharmaMar; fees: Lilly, PharmaMar. TB: has received travel fees from PARI GmbH. JTS: honoraria as consultant or for continuing medical education presentations: AstraZeneca, Bayer, Immunocore, Novartis, Roche/Genentech, Servier. His institution receives research funding from Bristol-Myers Squibb, Celgene, Eisbach, Bio, Roche/Genentech; He holds ownership and serves on the Board of Directors of Pharma15. TBr: has received a Clinician Scientist Stipend of the UMEA sponsored by the faculty of medicine and DFG; travel fees: DGE, Eisai; speaker honoraria: Liberum, Eisai, Eli Lilly; Ad Boards: Eli Lilly, Eisai, Bayer Pharma; consultant/Clinical Studies: Eli Lilly. KH: personal fees: Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis, Oncology, Pharma15; non-financial support: ABX; grants/personal fees: BTG. WPF: SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker), Eczacıbaşı Monrol (speaker). All other authors have no competing interest to disclose.